Editas Lays Off 65% Staff Amidst Reni-cel Development Halt and Strategic Shift to In Vivo Gene Editing

Editas Medicine announced a significant restructuring plan involving the layoff of approximately two-thirds of its workforce, which translates to around 180 employees, as part of a strategic shift towards in vivo gene editing[1][2]. This decision comes after an unsuccessful attempt to find a commercial partner for its lead CRISPR-based therapy, reni-cel, which targeted sickle cell disease. Consequently, the development of reni-cel will be discontinued, impacting ongoing trials and resulting in the departure of key personnel, including the Chief Medical Officer and two board members[1][2]. With a renewed focus on in vivo therapies, Editas aims to lead in the CRISPR-edited medicine field, bolstering its approach through technological advancements and streamlined operations[1][2].